SCA
TAK icon

Stuart Chaussee & Associates’s Takeda Pharmaceutical TAK Stock Holding History

Stuart Chaussee & Associates’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,636
Closed -$33K – 133
2019
Q1 		$33K Buy
+1,636
New +$32.9K 0.02% 54

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stuart Chaussee & Associates's TAK Position: Q2 2019 in Review

Stuart Chaussee & Associates sold out of Takeda Pharmaceutical (TAK) in Q2 2019, closing a stake of 1,636 shares — an estimated $33K sold.

Stuart Chaussee & Associates first reported a position in TAK in Q1 2019 and held it in 1 quarter. The position peaked at $33K in Q1 2019. 347 funds tracked by Wall St. Rank hold TAK as of Q2 2019.

  • Stuart Chaussee & Associates reported no remaining Takeda Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 1,636 Takeda Pharmaceutical shares in Q2 2019, an estimated $33K.
  • Stuart Chaussee & Associates first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • Stuart Chaussee & Associates's Takeda Pharmaceutical position peaked at $33K in Q1 2019.
  • 347 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2019.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2019, filed 8 Aug 2019.